Guru Fundamental Report for ABBV

According to Validea's guru fundamental report, AbbVie (ABBV) receives a 77% rating based on Partha Mohanram's P/B Growth Investor model, which favors low book-to-market stocks with sustained growth characteristics. The model gives AbbVie passing grades on key metrics like book-to-market ratio, return on assets, and sales variance, but flags the company for its capital expenditures to assets and research and development to assets ratios. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Analysis

AbbVie Inc. (ABBV) has received a 77% rating from Validea's P/B Growth Investor model, based on Partha Mohanram's strategy which targets low book-to-market stocks demonstrating characteristics of sustained future growth. This rating places ABBV near, but slightly below, the 80% threshold that typically signals model interest, with strong interest usually indicated above 90%. The analysis reveals that ABBV passes several key fundamental tests within this model, including book/market ratio, return on assets, cash flow from operations to assets, the relationship between cash flow and return on assets, return on assets variance, sales variance, and advertising to assets. These passes suggest underlying strengths in profitability, operational efficiency, and sales consistency. However, the model flags ABBV with a 'FAIL' on two criteria: capital expenditures to assets and research and development to assets. These failures might indicate areas where the company's investment in future growth, through capital projects or innovation, does not align optimally with the model's specific parameters for sustained growth, despite its large-cap status in the Biotechnology & Drugs industry.

Key Decisions for Investors

• Investors should consider AbbVie's moderately positive assessment under this specific growth model, noting its strengths in profitability and sales metrics but also recognizing the 77% score is just shy of the model's typical interest threshold.
• Further investigation into AbbVie's capital expenditure and R&D to asset ratios is warranted to understand the potential implications of these 'FAIL' ratings on its long-term growth trajectory, particularly in the R&D-intensive biotechnology sector.
• While the model highlights several favorable fundamental characteristics, investors should weigh these specific model-driven insights, including its flagged weaknesses, within the context of their broader investment strategy and risk assessment for ABBV.